FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024672831> ?p ?o ?g. }

• W2024672831 endingPage "6290" @default.
• W2024672831 startingPage "6290" @default.
• W2024672831 abstract "To compare the effects of telbivudine (LDT) and entecavir (ETV) in treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B by meta-analysis.We conducted a literature search using PubMed, MEDLINE, EMBASE, the China National Knowledge Infrastructure, the VIP database, the Wanfang database and the Cochrane Controlled Trial Register for all relevant articles published before April 1, 2012. Randomized controlled trials (RCTs) comparing LDT with ETV for treatment of HBeAg-positive chronic hepatitis B were included. The data was analyzed with Review Manager Software 5.0. We used relative risk (RR) as an effect measure, and reported its 95% CI. Meta-analysis was performed using either a fixed-effect or random-effect model, based on the absence or presence of significant heterogeneity. Two reviewers assessed the risk of bias and extracted data independently and in duplicate. The analysis was executed using the main outcome parameters including hepatitis B virus (HBV) DNA undetectability, alanine aminotransferase (ALT) normalization, HBeAg loss, HBeAg seroconversion, drug-resistance, and adverse reactions. Meta-analysis of the included trials and subgroup analyses were conducted to examine the association between pre-specified characteristics with the therapeutic effects of the two agents.Thirteen eligible trials (3925 patients in total) were included and evaluated for methodological quality and heterogeneity. In various treatment durations of 4 wk, 8 wk, 12 wk, 24 wk, 36 wk, 48 wk, 52 wk, 60 wk and 72 wk, the rates of HBV DNA undetectability and ALT normalization in the two groups were similar, without statistical significance. At 4 wk and 8 wk of the treatment, no statistical differences were found in the rate of HBeAg loss between the two groups, while the rate in the LDT group was higher than in the ETV group at 12 wk, 24 wk, 48 wk and 52 wk, respectively (RR 2.28, 95% CI 1.16, 7.03, P = 0.02; RR 1.45, 95% CI 1.16, 1.82, P = 0.001; RR 1.45, 95% CI 1.11, 1.89, P = 0.006; and RR 1.86, 95% CI 1.04, 3.32, P = 0.04). At 4 wk, 8 wk, 60 wk and 72 wk of the treatment, there were no significant differences in the rate of HBeAg seroconversion between the two groups, while at 12 wk, 24 wk, 48 wk and 52 wk, the rate in the LDT group was higher than in the ETV group (RR 2.10, 95% CI 1.36, 3.24, P = 0.0008; RR 1.71, 95% CI 1.29, 2.28, P = 0.0002; RR 1.86, 95% CI 1.36, 2.54, P < 0.0001; and RR 1.87, 95% CI 1.21, 2.90, P = 0.005). The rate of drug-resistance was higher in the LDT group than in the ETV group (RR 3.76, 95% CI 1.28, 11.01, P = 0.02). In addition, no severe adverse drug reactions were observed in the two groups. And the rate of increased creatine kinase in the LDT group was higher than in the ETV group (RR 5.58, 95% CI 2.22, 13.98, P = 0.0002).LDT and ETV have similar virological and biomedical responses, and both are safe and well tolerated. However, LDT has better serological response and higher drug-resistance." @default.
• W2024672831 created "2016-06-24" @default.
• W2024672831 creator A5044174491 @default.
• W2024672831 creator A5090079609 @default.
• W2024672831 date "2012-01-01" @default.
• W2024672831 modified "2023-10-18" @default.
• W2024672831 title "Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis" @default.
• W2024672831 cites W1581157337 @default.
• W2024672831 cites W1598602811 @default.
• W2024672831 cites W1976104517 @default.
• W2024672831 cites W1978314081 @default.
• W2024672831 cites W2001248409 @default.
• W2024672831 cites W2009466011 @default.
• W2024672831 cites W2011946598 @default.
• W2024672831 cites W2014279976 @default.
• W2024672831 cites W2027543203 @default.
• W2024672831 cites W2042033552 @default.
• W2024672831 cites W2064551296 @default.
• W2024672831 cites W2089153567 @default.
• W2024672831 cites W2098359965 @default.
• W2024672831 cites W2104389844 @default.
• W2024672831 cites W2123543307 @default.
• W2024672831 cites W2134972120 @default.
• W2024672831 cites W2135386419 @default.
• W2024672831 cites W2140784287 @default.
• W2024672831 cites W2143216061 @default.
• W2024672831 cites W2143584498 @default.
• W2024672831 cites W2159431812 @default.
• W2024672831 cites W2167744756 @default.
• W2024672831 cites W231105904 @default.
• W2024672831 cites W2360715215 @default.
• W2024672831 cites W2371285295 @default.
• W2024672831 cites W2393822184 @default.
• W2024672831 cites W2410551403 @default.
• W2024672831 cites W2412437957 @default.
• W2024672831 cites W3030413268 @default.
• W2024672831 doi "https://doi.org/10.3748/wjg.v18.i43.6290" @default.
• W2024672831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3501779" @default.
• W2024672831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23180951" @default.
• W2024672831 hasPublicationYear "2012" @default.
• W2024672831 type Work @default.
• W2024672831 sameAs 2024672831 @default.
• W2024672831 citedByCount "12" @default.
• W2024672831 countsByYear W20246728312013 @default.
• W2024672831 countsByYear W20246728312014 @default.
• W2024672831 countsByYear W20246728312015 @default.
• W2024672831 countsByYear W20246728312016 @default.
• W2024672831 countsByYear W20246728312017 @default.
• W2024672831 countsByYear W20246728312019 @default.
• W2024672831 countsByYear W20246728312020 @default.
• W2024672831 countsByYear W20246728312021 @default.
• W2024672831 crossrefType "journal-article" @default.
• W2024672831 hasAuthorship W2024672831A5044174491 @default.
• W2024672831 hasAuthorship W2024672831A5090079609 @default.
• W2024672831 hasBestOaLocation W20246728311 @default.
• W2024672831 hasConcept C126322002 @default.
• W2024672831 hasConcept C168563851 @default.
• W2024672831 hasConcept C187960798 @default.
• W2024672831 hasConcept C203014093 @default.
• W2024672831 hasConcept C2522874641 @default.
• W2024672831 hasConcept C2775940106 @default.
• W2024672831 hasConcept C2776175608 @default.
• W2024672831 hasConcept C2777382497 @default.
• W2024672831 hasConcept C2777410769 @default.
• W2024672831 hasConcept C2777869810 @default.
• W2024672831 hasConcept C2780439572 @default.
• W2024672831 hasConcept C2780593183 @default.
• W2024672831 hasConcept C2781144229 @default.
• W2024672831 hasConcept C44249647 @default.
• W2024672831 hasConcept C65409693 @default.
• W2024672831 hasConcept C71924100 @default.
• W2024672831 hasConcept C82789193 @default.
• W2024672831 hasConcept C90924648 @default.
• W2024672831 hasConcept C95190672 @default.
• W2024672831 hasConceptScore W2024672831C126322002 @default.
• W2024672831 hasConceptScore W2024672831C168563851 @default.
• W2024672831 hasConceptScore W2024672831C187960798 @default.
• W2024672831 hasConceptScore W2024672831C203014093 @default.
• W2024672831 hasConceptScore W2024672831C2522874641 @default.
• W2024672831 hasConceptScore W2024672831C2775940106 @default.
• W2024672831 hasConceptScore W2024672831C2776175608 @default.
• W2024672831 hasConceptScore W2024672831C2777382497 @default.
• W2024672831 hasConceptScore W2024672831C2777410769 @default.
• W2024672831 hasConceptScore W2024672831C2777869810 @default.
• W2024672831 hasConceptScore W2024672831C2780439572 @default.
• W2024672831 hasConceptScore W2024672831C2780593183 @default.
• W2024672831 hasConceptScore W2024672831C2781144229 @default.
• W2024672831 hasConceptScore W2024672831C44249647 @default.
• W2024672831 hasConceptScore W2024672831C65409693 @default.
• W2024672831 hasConceptScore W2024672831C71924100 @default.
• W2024672831 hasConceptScore W2024672831C82789193 @default.
• W2024672831 hasConceptScore W2024672831C90924648 @default.
• W2024672831 hasConceptScore W2024672831C95190672 @default.
• W2024672831 hasIssue "43" @default.
• W2024672831 hasLocation W20246728311 @default.
• W2024672831 hasLocation W20246728312 @default.
• W2024672831 hasLocation W20246728313 @default.
• W2024672831 hasLocation W20246728314 @default.

• next